Mechanism of Action of Novel Anticancer Drugs in Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 30 May 2026 | Viewed by 1
Special Issue Editor
Special Issue Information
Dear Colleagues,
With rapid advances in biotechnology and data science, cancer research is entering a new era defined by mechanisms of action. FDA trends show a major shift from cytotoxic chemotherapies to targeted drugs and biologics, emphasizing precision over tumor site. Kinase inhibitors and immune checkpoint inhibitors now dominate new approvals, while multi-omic sequencing and AI-driven analytics have accelerated biomarker discovery and tumor-agnostic strategies. Novel approaches target cancer stemness, cellular plasticity, and resistance to prior treatment—including immunotherapies—and aim to drug previously “undruggable” molecules such as KRAS and p53. Despite impressive gains, metastasis remains the major clinical barrier. The expanding landscape of mechanism-based therapies and combinatorial strategies offers new opportunities to identify vulnerabilities and improve durable responses in advanced cancers.
Dr. Ruifang Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- immunotherapy
- tumor-agostic approval
- therapy resistence
- mechaninsm of action
- kinase inhibitor
- immune checkpoint inhibitor
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
